Illumina, Inc. $ILMN Stock Holdings Lessened by Ameritas Investment Partners Inc.

Ameritas Investment Partners Inc. reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 30,735 shares of the life sciences company’s stock after selling 431 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Illumina were worth $2,932,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the stock. Envestnet Portfolio Solutions Inc. boosted its stake in shares of Illumina by 0.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after buying an additional 99 shares during the period. Parkside Financial Bank & Trust raised its holdings in shares of Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares in the last quarter. Moors & Cabot Inc. boosted its position in Illumina by 2.5% during the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company’s stock valued at $465,000 after purchasing an additional 145 shares during the last quarter. Arkadios Wealth Advisors boosted its position in Illumina by 1.7% during the second quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock valued at $871,000 after purchasing an additional 157 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. grew its stake in Illumina by 3.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company’s stock valued at $445,000 after purchasing an additional 164 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 1.7%

Shares of NASDAQ:ILMN opened at $125.96 on Tuesday. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $153.06. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The company has a market cap of $19.25 billion, a P/E ratio of 15.94, a P/E/G ratio of 2.34 and a beta of 1.42. The stock’s 50-day moving average is $105.72 and its 200-day moving average is $98.01.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm’s revenue for the quarter was up .4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Cowen reaffirmed a “hold” rating on shares of Illumina in a research note on Friday, October 31st. TD Cowen increased their price objective on Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a report on Friday, October 31st. Robert W. Baird set a $109.00 target price on shares of Illumina in a research note on Friday, October 31st. Barclays boosted their target price on shares of Illumina from $95.00 to $100.00 and gave the stock an “underweight” rating in a research report on Friday, October 31st. Finally, Evercore ISI raised their price target on shares of Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Five analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $115.00.

Insider Activity

In related news, Director Scott Gottlieb bought 500 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were acquired at an average price of $122.13 per share, with a total value of $61,065.00. Following the completion of the transaction, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. The trade was a 4.16% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.60% of the company’s stock.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.